Search Results - "VERHEUL, Henk"

Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action? by Gotink, Kristy J., Verheul, Henk M. W.

“…Tyrosine kinases are important cellular signaling proteins that have a variety of biological activities including cell proliferation and migration. Multiple…”
Get full text

Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition by Pinedo, Herbert M, Verheul, Henk. M. W

“…Contrary to initial expectations, angiogenesis inhibitors can cause toxicities in patients with cancer. The toxicity profiles of these inhibitors reflect the…”
Get full text

Lysosomal Sequestration of Sunitinib: A Novel Mechanism of Drug Resistance by GOTINK, Kristy J, BROXTERMAN, Henk J, GRIFFIOEN, Arjan W, ASSARAF, Yehuda G, PILI, Roberto, PETERS, Godefridus J, VERHEUL, Henk M. W, LABOTS, Mariette, DE HAAS, Richard R, DEKKER, Henk, HONEYWELL, Richard J, RUDEK, Michelle A, BEEREPOOT, Laurens V, MUSTERS, René J, JANSEN, Gerrit

“…Resistance to antiangiogenic tyrosine kinase inhibitors such as sunitinib is an important clinical problem, but its underlying mechanisms are largely unknown…”
Get full text

RNA-Seq of Tumor-Educated Platelets Enables Blood-Based Pan-Cancer, Multiclass, and Molecular Pathway Cancer Diagnostics by Best, Myron G., Sol, Nik, Kooi, Irsan, Tannous, Jihane, Westerman, Bart A., Rustenburg, François, Schellen, Pepijn, Verschueren, Heleen, Post, Edward, Koster, Jan, Ylstra, Bauke, Ameziane, Najim, Dorsman, Josephine, Smit, Egbert F., Verheul, Henk M., Noske, David P., Reijneveld, Jaap C., Nilsson, R. Jonas A., Tannous, Bakhos A., Wesseling, Pieter, Wurdinger, Thomas

“…Tumor-educated blood platelets (TEPs) are implicated as central players in the systemic and local responses to tumor growth, thereby altering their RNA…”
Get full text

Combination of NK Cells and Cetuximab to Enhance Anti-Tumor Responses in RAS Mutant Metastatic Colorectal Cancer by Veluchamy, John Pradeep, Spanholtz, Jan, Tordoir, Marleen, Thijssen, Victor L, Heideman, Daniëlle A M, Verheul, Henk M W, de Gruijl, Tanja D, van der Vliet, Hans J

“…The ability of Natural Killer (NK) cells to kill tumor targets has been extensively studied in various hematological malignancies. However, NK cell therapy…”
Get full text

A first-in-man phase 1 study of the DNA-dependent protein kinase inhibitor peposertib (formerly M3814) in patients with advanced solid tumours by van Bussel, Mark T. J., Awada, Ahmad, de Jonge, Maja J. A., Mau-Sørensen, Morten, Nielsen, Dorte, Schöffski, Patrick, Verheul, Henk M. W., Sarholz, Barbara, Berghoff, Karin, El Bawab, Samer, Kuipers, Mirjam, Damstrup, Lars, Diaz-Padilla, Ivan, Schellens, Jan H. M.

“…Background This open-label, phase 1 trial (NCT02316197) aimed to determine the maximum-tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of…”
Get full text

Limited evolution of the actionable metastatic cancer genome under therapeutic pressure by van de Haar, Joris, Hoes, Louisa R., Roepman, Paul, Lolkema, Martijn P., Verheul, Henk M. W., Gelderblom, Hans, de Langen, Adrianus J., Smit, Egbert F., Cuppen, Edwin, Wessels, Lodewyk F. A., Voest, Emile E.

“…Genomic profiling is critical for the identification of treatment options for patients with metastatic cancer, but it remains unclear how frequently this…”
Get full text

Loss of Muscle Mass During Chemotherapy Is Predictive for Poor Survival of Patients With Metastatic Colorectal Cancer by Blauwhoff-Buskermolen, Susanne, Versteeg, Kathelijn S, de van der Schueren, Marian A E, den Braver, Nicole R, Berkhof, Johannes, Langius, Jacqueline A E, Verheul, Henk M W

“…Low muscle mass is present in approximately 40% of patients with metastatic colorectal cancer (mCRC) and may be associated with poor outcome. We studied change…”
Get full text

Treatment outcome of patients with recurrent glioblastoma multiforme: a retrospective multicenter analysis by van Linde, Myra E., Brahm, Cyrillo G., de Witt Hamer, Philip C., Reijneveld, Jaap C., Bruynzeel, Anna M. E., Vandertop, W. Peter, van de Ven, Peter M., Wagemakers, Michiel, van der Weide, Hiske L., Enting, Roelien H., Walenkamp, Annemiek M. E., Verheul, Henk M. W.

“…Glioblastoma multiforme (GBM) universally recurs with dismal prognosis. We evaluated the efficacy of standard treatment strategies for patients with recurrent…”
Get full text

γδ T cells are effectors of immunotherapy in cancers with HLA class I defects by de Vries, Natasja L., van de Haar, Joris, Veninga, Vivien, Chalabi, Myriam, Ijsselsteijn, Marieke E., van der Ploeg, Manon, van den Bulk, Jitske, Ruano, Dina, van den Berg, Jose G., Haanen, John B., Zeverijn, Laurien J., Geurts, Birgit S., de Wit, Gijs F., Battaglia, Thomas W., Gelderblom, Hans, Verheul, Henk M. W., Schumacher, Ton N., Wessels, Lodewyk F. A., Koning, Frits, de Miranda, Noel F. C. C., Voest, Emile E.

“…DNA mismatch repair-deficient (MMR-d) cancers present an abundance of neoantigens that is thought to explain their exceptional responsiveness to immune…”
Get full text

Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial by Shapiro, Joel, Dr, van Lanschot, J Jan B, Prof, Hulshof, Maarten C C M, MD, van Hagen, Pieter, MD, van Berge Henegouwen, Mark I, MD, Wijnhoven, Bas P L, MD, van Laarhoven, Hanneke W M, Prof, Nieuwenhuijzen, Grard A P, MD, Hospers, Geke A P, Prof, Bonenkamp, Johannes J, MD, Cuesta, Miguel A, Prof, Blaisse, Reinoud J B, MD, Busch, Olivier R C, Prof, ten Kate, Fiebo J W, Prof, Creemers, Geert-Jan M, MD, Punt, Cornelis J A, Prof, Plukker, John Th M, Prof, Verheul, Henk M W, Prof, Bilgen, Ernst J Spillenaar, MD, van Dekken, Herman, MD, van der Sangen, Maurice J C, MD, Rozema, Tom, MD, Biermann, Katharina, MD, Beukema, Jannet C, MD, Piet, Anna H M, MD, van Rij, Caroline M, MD, Reinders, Janny G, MD, Tilanus, Hugo W, Prof, Steyerberg, Ewout W, Prof, van der Gaast, Ate, MD

“…Summary Background Initial results of the ChemoRadiotherapy for Oesophageal cancer followed by Surgery Study (CROSS) comparing neoadjuvant chemoradiotherapy…”
Get full text

The Rise of Allogeneic Natural Killer Cells As a Platform for Cancer Immunotherapy: Recent Innovations and Future Developments by Veluchamy, John P, Kok, Nina, van der Vliet, Hans J, Verheul, Henk M W, de Gruijl, Tanja D, Spanholtz, Jan

“…Natural killer (NK) cells are critical immune effector cells in the fight against cancer. As NK cells in cancer patients are highly dysfunctional and reduced…”
Get full text

Understanding the causes of multidrug resistance in cancer: a comparison of doxorubicin and sunitinib by Broxterman, Henk J, Gotink, Kristy J, Verheul, Henk M.W

“…Abstract Multiple molecular, cellular, micro-environmental and systemic causes of anticancer drug resistance have been identified during the last 25 years. At…”
Get full text

The Current Status of Immune Checkpoint Inhibitors in Neuro-Oncology: A Systematic Review by Brahm, Cyrillo G, van Linde, Myra E, Enting, Roelien H, Schuur, Maaike, Otten, René H J, Heymans, Martijn W, Verheul, Henk M W, Walenkamp, Annemiek M E

“…The introduction of immune checkpoint inhibitors (ICI), as a novel treatment modality, has transformed the field of oncology with unprecedented successes…”
Get full text

Rapid Decrease in Delivery of Chemotherapy to Tumors after Anti-VEGF Therapy: Implications for Scheduling of Anti-Angiogenic Drugs by Van der Veldt, Astrid A.M., Lubberink, Mark, Bahce, Idris, Walraven, Maudy, de Boer, Michiel P., Greuter, Henri N.J.M., Hendrikse, N. Harry, Eriksson, Jonas, Windhorst, Albert D., Postmus, Pieter E., Verheul, Henk M., Serné, Erik H., Lammertsma, Adriaan A., Smit, Egbert F.

“…Current strategies combining anti-angiogenic drugs with chemotherapy provide clinical benefit in cancer patients. It is assumed that anti-angiogenic drugs,…”
Get full text

Locoregionally Recurrent Colon Cancer: How Far Have We Come? A Population-Based, Retrospective Cohort Study by Swartjes, Hidde, van Lankveld, Daan W. P., van Erning, Felice N., Verheul, Henk M. W., de Wilt, Johannes H. W., Koëter, Tijmen, Vissers, Pauline A. J.

“…Background The reported outcomes of locoregionally recurrent colon cancer (LRCC) are poor, but the literature about LRCC is scarce and aged. Recent…”
Get full text

Development of bioluminescent chick chorioallantoic membrane (CAM) models for primary pancreatic cancer cells: a platform for drug testing by Rovithi, Maria, Avan, Amir, Funel, Niccola, Leon, Leticia G., Gomez, Valentina E., Wurdinger, Thomas, Griffioen, Arjan W., Verheul, Henk M. W., Giovannetti, Elisa

“…The aim of the present study was to develop chick-embryo chorioallantoic membrane (CAM) bioluminescent tumor models employing low passage cell cultures…”
Get full text

Evaluation of several methodological challenges in circulating miRNA qPCR studies in patients with head and neck cancer by Poel, Dennis, Buffart, Tineke E, Oosterling-Jansen, Jolanda, Verheul, Henk MW, Voortman, Jens

“…Circulating microRNAs (ci-miRNAs) in blood have emerged as promising diagnostic, prognostic and predictive biomarkers in cancer. Many clinical studies…”
Get full text

The influence of different muscle mass measurements on the diagnosis of cancer cachexia by Blauwhoff‐Buskermolen, Susanne, Langius, Jacqueline A.E., Becker, Annemarie, Verheul, Henk M.W., Schueren, Marian A.E.

“…Background Progressive loss of muscle mass is a major characteristic of cancer cachexia. Consensus definitions for cachexia provide different options to…”
Get full text

White blood cell and cell-free DNA analyses for detection of residual disease in gastric cancer by Leal, Alessandro, van Grieken, Nicole C. T., Palsgrove, Doreen N., Phallen, Jillian, Medina, Jamie E., Hruban, Carolyn, Broeckaert, Mark A. M., Anagnostou, Valsamo, Adleff, Vilmos, Bruhm, Daniel C., Canzoniero, Jenna V., Fiksel, Jacob, Nordsmark, Marianne, Warmerdam, Fabienne A. R. M., Verheul, Henk M. W., van Spronsen, Dick Johan, Beerepoot, Laurens V., Geenen, Maud M., Portielje, Johanneke E. A., Jansen, Edwin P. M., van Sandick, Johanna, Meershoek-Klein Kranenbarg, Elma, van Laarhoven, Hanneke W. M., van der Peet, Donald L., van de Velde, Cornelis J. H., Verheij, Marcel, Fijneman, Remond, Scharpf, Robert B., Meijer, Gerrit A., Cats, Annemieke, Velculescu, Victor E.

“…Liquid biopsies are providing new opportunities for detection of residual disease in cell-free DNA (cfDNA) after surgery but may be confounded through…”
Get full text